Weight loss · Idaho
Weight loss and obesity studies in Idaho
19 studies have at least one recruiting site in Idaho. Weight-management research includes trials of new medicines, devices, diets and lifestyle programs for people with overweight or obesity, and studies of weight-related conditions such as fatty liver disease.
19 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Meridian, ID + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Meridian, ID + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Blackfoot, ID + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Blackfoot, ID + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Ammon, ID + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Rexburg, ID + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Meridian, ID + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly and Company
- Location
- Ammon, ID + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Ammon, ID + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Idaho Falls, ID + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Ammon, ID + 42 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Idaho Falls, ID + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Idaho Falls, ID + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Meridian, ID + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
- Location
- Meridian, ID + 26 other US sites
- Eligibility basics
- Ages 8–18
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
- Location
- Idaho Falls, ID + 55 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Meridian, ID + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and…
Novo Nordisk A/S
- Location
- Idaho Falls, ID + 55 other US sites
- Eligibility basics
- Ages 45+
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk A/S
- Location
- Blackfoot, ID + 18 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Can I join a weight loss study if I already take a GLP-1 medicine?
It depends on the study. Many exclude people currently or recently on weight-loss medicines; others are designed specifically for them. The listing’s eligibility criteria and the study team are the only reliable answer.